S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
WARNING TO ALL U.S. INVESTORS (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Sell every Stock except ONE (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
WARNING TO ALL U.S. INVESTORS (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Sell every Stock except ONE (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
WARNING TO ALL U.S. INVESTORS (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Sell every Stock except ONE (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
WARNING TO ALL U.S. INVESTORS (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Sell every Stock except ONE (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Sell every Stock except ONE (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:CRBP

Corbus Pharmaceuticals (CRBP) Earnings Date, Estimates & Call Transcripts

$9.92
-0.49 (-4.71%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$9.81
▼
$10.61
50-Day Range
$6.39
▼
$12.00
52-Week Range
$2.11
▼
$13.17
Volume
32,600 shs
Average Volume
309,315 shs
Market Capitalization
$41.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 8Estimated
Actual EPS
(Mar. 7)
-$2.61 Missed By -$0.51
Consensus EPS
(Mar. 7)
-$2.10
Last Year's Q1 EPS
(3/8/2022)
-$0.08
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

CRBP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CRBP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Corbus Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($4.09)($2.82)($3.46)
Q2 20232($3.07)($2.35)($2.71)
Q3 20232($3.34)($2.39)($2.87)
Q4 20232($3.64)($2.42)($3.03)
FY 20238($14.14)($9.98)($12.06)

CRBP Earnings Date and Information

Corbus Pharmaceuticals last posted its earnings data on March 7th, 2023. The biopharmaceutical company reported ($2.61) EPS for the quarter, missing the consensus estimate of ($2.10) by $0.51. Corbus Pharmaceuticals has generated ($12.26) earnings per share over the last year (($12.26) diluted earnings per share). Earnings for Corbus Pharmaceuticals are expected to grow in the coming year, from ($7.30) to ($4.93) per share. Corbus Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 8th, 2023 based off prior year's report dates.

Corbus Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/8/2023
(Estimated)		        
5/9/2023Q1 2023($4.09)($4.24)($0.15)($4.24)
3/7/2023Q4 2022($2.10)($2.61)($0.51)($2.61)
11/8/2022Q3 2022($0.06)($0.07)($0.01)($0.07)
8/9/2022Q2 2022($0.06)($0.07)($0.01)($0.03)
5/10/2022Q1 2022($0.09)($0.08)+$0.01($0.08)    
3/8/2022Q4 2021($0.11)($0.08)+$0.03($0.08)
11/12/20219/30/2021($0.12)($0.02)+$0.10($0.02)$0.81 million$0.10 million
8/12/20216/30/2021($0.12)($0.15)($0.03)($0.15)$0.83 million$0.14 million
5/13/2021Q1 2021($0.15)($0.14)+$0.01($0.14)$0.95 million$0.65 million  
3/14/202112/31/2020($0.25)($0.10)+$0.15($0.10)$1.24 million$0.66 million  
11/16/20209/30/2020($0.42)($0.42)($0.43)$3.42 million$1.23 million  
8/6/20206/30/2020($0.39)($0.52)($0.13)($0.52)$3.90 million$0.29 million  
5/11/20203/31/2020($0.40)($0.43)($0.03)($0.43)$1.64 million$1.76 million  
3/12/202012/31/2019($0.36)($0.41)($0.05)($0.41)$4.64 million$2.57 million  
11/7/2019Q3($0.36)($0.32)+$0.04($0.32)$1.73 million$2.59 million  
8/8/2019Q2 2019($0.22)$0.03+$0.25$0.03$10.32 million$29.10 million
5/9/20193/31/2019$0.02($0.43)($0.45)($0.43)$20.97 million$1.89 million
3/12/201912/31/2018($0.23)($0.30)($0.07)($0.30)$1.99 million$1.93 million
11/8/20189/30/2018($0.21)($0.26)($0.05)($0.26)$1.66 million$1.09 million
8/8/2018Q2 2018($0.2150)($0.21)+$0.0050($0.21)$1.90 million$0.85 million
5/10/2018Q1 2018($0.10)($0.21)($0.11)($0.21)$6.25 million$0.95 million
3/12/2018Q4 2017($0.1550)($0.20)($0.0450)($0.20)
11/8/2017Q3 2017($0.16)($0.14)+$0.02($0.14)$0.80 million
8/9/2017Q2 2017($0.19)($0.15)+$0.04($0.15)$0.50 million$0.35 million
5/9/2017Q1 2017($0.16)($0.16)($0.16)$2.50 million$1.29 million
3/9/2017Q4 2016($0.1220)($0.18)($0.0580)($0.18)$1.50 million$0.38 million
11/10/2016Q3 2016($0.10)($0.12)($0.02)($0.12)$1.00 million$0.74 million
8/15/2016Q216($0.08)($0.11)($0.03)($0.11)$1.25 million$0.40 million
5/16/2016Q116($0.08)($0.08)($0.08)$0.40 million
3/29/2016Q4 2015($0.06)($0.06)($0.06)$1.25 million$0.36 million
11/10/2015Q315($0.08)($0.06)+$0.02($0.06)$0.17 million
8/13/2015Q2 2015($0.06)($0.10)($0.04)($0.10)$0.11 million
5/13/2015Q1 2015($0.05)($0.06)($0.01)($0.06)
2/10/2015Q4 2014($0.03)($0.06)($0.03)($0.06)












Corbus Pharmaceuticals Earnings - Frequently Asked Questions

When is Corbus Pharmaceuticals's earnings date?

Corbus Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 8th, 2023 based off last year's report dates. Learn more on CRBP's earnings history.

Did Corbus Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Corbus Pharmaceuticals (NASDAQ:CRBP) missed the analysts' consensus estimate of ($2.10) by $0.51 with a reported earnings per share (EPS) of ($2.61). Learn more on analysts' earnings estimate vs. CRBP's actual earnings.

How much revenue does Corbus Pharmaceuticals generate each year?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a recorded annual revenue of $880,000.00.

How much profit does Corbus Pharmaceuticals generate each year?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a recorded net income of -$42.35 million. CRBP has generated -$12.26 earnings per share over the last four quarters.

What is Corbus Pharmaceuticals's EPS forecast for next year?

Corbus Pharmaceuticals's earnings are expected to grow from ($7.30) per share to ($4.93) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:CRBP) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -